In recent years, immune checkpoint inhibitors (ICIs) have emerged as a significant breakthrough in cancer therapy, reshaping traditional treatment paradigms. PD-1/PD-L1 pathway inhibitors have been widely used across various cancer treatments, demonstrating impressive efficacy. As PD-(L)1 inhibitor therapies continue to mature, pharmaceutical giants have turned their attention to PD-(L)1...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek